Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era / 中国癌症杂志

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in terms of molecular pathogenesis and cell of origin. Earlier prognostic models relied mainly on such clinical variables as age, stage of disease, and performance status, which did not display its heterogeneity. Many studies have reported that some biomarkers could be used for prognostication, while older prognostic models need to be revalidated and modified as improved therapeutic options become available. In this review, we discussed pertinent studies on individual biomarkers and pattern-based biomarker models, with an emphasis on markers evaluated in patients treated with rituximab-containing chemotherapy.